INVENTIVA : Inventiva Annonce les Conclusions Positives du DSMB de l'Etude de Phase IIb FASST dans la Sclérodermie Systémique avec le Lanifibranor
04 janv. 2018 11h45 HE
|
INVENTIVA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
...
INVENTIVA : Inventiva Announces Positive DSMB Review in Phase IIb FASST Trial in Systemic Sclerosis with Lanifibranor
04 janv. 2018 11h45 HE
|
INVENTIVA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Inventiva Announces Positive DSMB...
Inventiva annonce l'inclusion du premier patient dans son étude de phase IIa (iMProveS) menée avec odiparcil dans le traitement de la MPS VI
03 janv. 2018 11h45 HE
|
INVENTIVA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
...
Inventiva Announces Enrollment of First Patient into Its Odiparcil Phase IIa Trial (iMProveS) for MPS VI
03 janv. 2018 11h45 HE
|
INVENTIVA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Inventiva Announces Enrollment of...
Inventiva Announces Initiation of Phase IIb Clinical Trial of IVA337 for Treatment of Non-Alcoholic Steatohepatitis (NASH)
03 janv. 2017 08h00 HE
|
Inventiva Pharma
Therapeutic candidate IVA337 is a next generation PanPPAR agonist addressing all the relevant clinical and regulatory features of NASHNATIVE clinical study plans to enroll 225 patients in 12 European...